drugset / Trial / NCT00141713
The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease
NaSingle-groupOpen-labelTreatment
Summary
Etanercept (Enbrel) will be added to standard therapy for acute Graft-versus-Host Disease to see if the effectiveness of standard therapy can be improved. Partial Funding Source- FDA OOPD
Timeline
- Start
- 2003-10
- Primary completion
- 2006-11
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etanercept | Protein / enzyme biologic | 0.4 mg/kg | Subcutaneous |